GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige BioPharma Ltd (XKRX:950210) » Definitions » Gross Profit

Prestige BioPharma (XKRX:950210) Gross Profit : ₩2,843 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Prestige BioPharma Gross Profit?

Prestige BioPharma's gross profit for the three months ended in Sep. 2024 was ₩2,222 Mil. Prestige BioPharma's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was ₩2,843 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Prestige BioPharma's gross profit for the three months ended in Sep. 2024 was ₩2,222 Mil. Prestige BioPharma's Revenue for the three months ended in Sep. 2024 was ₩2,222 Mil. Therefore, Prestige BioPharma's Gross Margin % for the quarter that ended in Sep. 2024 was N/A%.

Prestige BioPharma had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Prestige BioPharma Gross Profit Historical Data

The historical data trend for Prestige BioPharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige BioPharma Gross Profit Chart

Prestige BioPharma Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
Gross Profit
- - - 161.84 689.08

Prestige BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.32 119.38 638.62 -137.09 2,221.65

Competitive Comparison of Prestige BioPharma's Gross Profit

For the Biotechnology subindustry, Prestige BioPharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige BioPharma's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prestige BioPharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Prestige BioPharma's Gross Profit falls into.



Prestige BioPharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Prestige BioPharma's Gross Profit for the fiscal year that ended in Jun. 2024 is calculated as

Gross Profit (A: Jun. 2024 )=Revenue - Cost of Goods Sold
=689.075 - 0
=689

Prestige BioPharma's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=2221.648 - 0
=2,222

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,843 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Prestige BioPharma's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=2,222 / 2221.648
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Prestige BioPharma  (XKRX:950210) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Prestige BioPharma had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage


Prestige BioPharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Prestige BioPharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige BioPharma Business Description

Traded in Other Exchanges
N/A
Address
2 Science Park Drive No. 04-13/14, Ascent Tower B, Singapore Science Park, Singapore, SGP, 118222
Prestige BioPharma Ltd is a biopharmaceutical company. The company is focused on the development of biosimilars and new antibody therapeutics. It focuses on oncology and immune disorders, developing new and similar antibody drugs for solid tumor, pancreatic cancer, and arthritis.

Prestige BioPharma Headlines

No Headlines